News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ALTANA Pharma AG (AAA): Once-Daily Alvesco Provides Comparable Relief Of Asthma Symptoms To Twice-Daily Budesonide And Fluticasone



10/19/2005 5:13:04 PM

BAD HOMBURG, Germany--(BUSINESS WIRE)--March 21, 2005--ALTANA Pharma, the pharmaceutical group of ALTANA AG (NYSE:AAA; FWB:ALT), presented data during the American Academy of Allergy, Asthma and Immunology's (AAAAI) 61st annual meeting, demonstrating that once-daily Alvesco(R) (ciclesonide), a new inhaled corticosteroid for the treatment of asthma, is comparable to already marketed twice-daily inhaled corticosteroids, budesonide and fluticasone propionate. "Often, patients will miss a dose of their asthma medication, which could increase the likelihood of serious asthma complications," noted principal investigator Professor H. Magnussen, Medical Director of the Centre of Pneumology and Thoracic Surgery in Grosshansdorf, Germany. "These findings are significant because they show that patients can control their symptoms with a once-daily inhalation like Alvesco, which may enhance compliance."

Read at BioSpace.com


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES